# DESCRIPTION

## STATEMENT OF GOVERNMENT INTEREST

- state government interest

## 1. BACKGROUND OF THE INVENTION

- introduce cancer statistics
- describe brain tumors
- motivate ATF5 research
- summarize ATF5 findings

## 2. SUMMARY OF THE INVENTION

- introduce CP-d/n-ATF5
- describe CP-d/n-ATF5 embodiments
- outline kit embodiments

## 4. DETAILED DESCRIPTION OF THE INVENTION

- define ATF5 protein
- describe ATF5 expression in various tumor types
- introduce ATF5 analogue
- define ATF5 biological activity
- describe interference with ATF5 function
- outline effect of ATF5 interference on glioblastoma multiforme tumors
- describe dominant-negative ATF5 (d/n-ATF5)
- provide d/n-ATF5 peptide sequences
- describe d/n-ATF5 encoding nucleic acid sequences
- introduce cell-penetrating peptide (CP)
- describe CP properties
- provide examples of CPs
- describe penetratin 1
- introduce CP-d/n-ATF5
- provide CP-d/n-ATF5 peptide sequences
- describe CP-d/n-ATF5 encoding nucleic acid sequences
- introduce alternative CPs
- provide examples of alternative CPs
- define MAPs
- describe covalent binding of cell-penetrating peptides to d/n-ATFS
- describe non-covalent linkage of d/n-ATF5 to cell-penetrating peptide
- describe chemical linkers for d/n-ATF5 and cell-penetrating peptide
- outline general strategy for conjugation
- describe synthesis of proteins and protein analogues
- define amino acid residues
- describe cell-penetrating dominant-negative ATFS sequences
- outline use of d/n-ATF5 compositions
- describe inhibition of ATF5 function or activity
- describe treatment or prevention of tumors using CP-d/n-ATF5
- define neural tumor
- classify brain tumors
- describe gliomas
- detail astrocytomas
- introduce ATF5 inhibitors
- list susceptible cell lines
- describe method of promoting apoptosis
- outline CP-d/n-ATF5 compositions
- formulate CP-d/n-ATF5 for oral administration
- formulate CP-d/n-ATF5 for parenteral administration
- prepare CP-d/n-ATF5 for intranasal delivery
- describe administration devices
- provide therapeutic compositions
- prepare CP-d/n-ATF5 formulations
- include other therapeutic agents
- provide kits for treating tumors

## 5. EXAMPLES

### 5.1 CP-d/n-ATF5 Example

- describe materials and methods
- truncate d/n ATF-5
- produce CP-6xHis-Pen-Flag-tagged-d/n-ATF5 protein
- perform bioassay of CP-6xHis-Pen-Flag-tagged-d/n-ATF5
- analyze mass spectroscopy
- perform LC-MS analysis
- determine bioactivity of pQC-eGFP-d/n ATF-5tr product
- image internalized Pen-d/n-ATF5-RP
- describe retrovirus-induced mouse glioblastoma model and treatment
- perform brain sectioning and staining
- generate cell-penetrating d/n-ATF5
- design penetratin sequence
- express and purify Pen-d/n-ATF5-RP
- verify molecular weight of Pen-d/n-ATF5-RP
- test stability of Pen-d/n-ATF5-RP in human serum
- demonstrate apoptosis of glioblastoma cells
- show systemic delivery of Pen-d/n-ATF5-RP
- assess therapeutic efficacy of Pen-d/n-ATF5-RP
- evaluate long-term survival and brain integrity
- compare with control peptide and untreated animals
- summarize results and implications
- present CP-d/n-ATF5 example
- discuss findings
- motivate treatment of malignant gliomas
- introduce additional cell lines and CP-din-ATF5 compositions
- demonstrate TAT-din-ATF5 promotes apoptotic death
- show TAT-din-ATF5 reduces expression of endogenous ATF5
- demonstrate TAT-din-ATF5 induces expression of pro-death gene DDIT3
- discuss synergistic effect of TAT-D/N-ATF5 with temozolomide
- present various assays demonstrating efficacy of TAT-D/N-ATF5 and PEN-D/N-ATF5

